ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.34 Insider Own0.10% Shs Outstand161.85M Perf Week7.29%
Market Cap3.22B Forward P/E- EPS next Y-0.88 Insider Trans-12.63% Shs Float161.70M Perf Month15.45%
Income-217.30M PEG- EPS next Q-0.24 Inst Own94.90% Short Float / Ratio4.96% / 6.89 Perf Quarter34.14%
Sales511.50M P/S6.30 EPS this Y41.60% Inst Trans0.92% Short Interest8.01M Perf Half Y20.92%
Book/sh2.63 P/B7.54 EPS next Y32.80% ROA-34.20% Target Price18.74 Perf Year-15.08%
Cash/sh2.68 P/C7.39 EPS next 5Y25.00% ROE-47.10% 52W Range12.24 - 28.06 Perf YTD24.87%
Dividend- P/FCF- EPS past 5Y14.90% ROI-31.60% 52W High-29.14% Beta0.59
Dividend %- Quick Ratio4.40 Sales past 5Y94.60% Gross Margin98.00% 52W Low62.42% ATR0.62
Employees510 Current Ratio4.50 Sales Q/Q-0.70% Oper. Margin-43.40% RSI (14)70.80 Volatility2.83% 3.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-86.70% Profit Margin-42.50% Rel Volume0.64 Prev Close19.83
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout- Avg Volume1.16M Price19.88
Recom2.60 SMA207.66% SMA5019.43% SMA20020.32% Volume248,645 Change0.25%
Jan-03-23Upgrade Guggenheim Neutral → Buy $22
Nov-04-22Downgrade Goldman Neutral → Sell $15 → $12
Nov-01-22Initiated Loop Capital Hold $17
Aug-08-22Downgrade Citigroup Buy → Neutral $19 → $15
Aug-05-22Downgrade Citigroup Buy → Neutral $19 → $15
Jun-21-22Downgrade Jefferies Buy → Underperform $25 → $10
Jun-16-22Upgrade Jefferies Hold → Buy $25
Mar-16-22Upgrade Canaccord Genuity Hold → Buy $30 → $31
Feb-09-22Upgrade H.C. Wainwright Neutral → Buy $36
Jan-05-22Upgrade Citigroup Neutral → Buy $30
Show Previous Ratings
Jan-09-23 09:00AM
Jan-03-23 11:58AM
Dec-21-22 04:05PM
04:05PM Loading…
Nov-08-22 04:05PM
Nov-03-22 12:23PM
Nov-02-22 05:35PM
Nov-01-22 10:04AM
Oct-27-22 04:05PM
Oct-26-22 10:02AM
Oct-20-22 04:05PM
12:02PM Loading…
Oct-19-22 12:02PM
Oct-13-22 07:30AM
Oct-12-22 10:57AM
Oct-06-22 01:36PM
Oct-04-22 02:19PM
Sep-13-22 08:44AM
Sep-12-22 07:30AM
Sep-07-22 11:30AM
Sep-01-22 09:03AM
Aug-30-22 09:55AM
Aug-26-22 12:00PM
Aug-09-22 01:24PM
Aug-08-22 05:35PM
04:05PM Loading…
Aug-05-22 07:55AM
Aug-04-22 11:39PM
Aug-01-22 10:01AM
Jul-27-22 08:23AM
Jul-25-22 04:05PM
Jul-19-22 11:22AM
Jul-18-22 04:07PM
Jul-08-22 11:14AM
Jun-21-22 12:07PM
Jun-17-22 08:00PM
Jun-16-22 03:42PM
Jun-15-22 04:53PM
Jun-03-22 11:31AM
May-19-22 09:01AM
May-05-22 10:06AM
May-04-22 06:15PM
May-03-22 04:05PM
May-02-22 04:05PM
Apr-27-22 03:03PM
Apr-21-22 09:09AM
Apr-19-22 05:52PM
Apr-18-22 04:05PM
Mar-30-22 11:30AM
Mar-25-22 02:26PM
Mar-22-22 09:00AM
Mar-10-22 04:05PM
Mar-09-22 08:30AM
Mar-03-22 09:00AM
Mar-01-22 09:43AM
Feb-28-22 05:35PM
Feb-21-22 03:00PM
Feb-17-22 04:28AM
Feb-16-22 09:00AM
Feb-14-22 09:00AM
Feb-11-22 09:00AM
Feb-02-22 01:38PM
Jan-13-22 11:13AM
Jan-11-22 11:56AM
Jan-10-22 01:20PM
Dec-22-21 05:24PM
Dec-21-21 04:12PM
Dec-20-21 04:05PM
Dec-14-21 09:00AM
Dec-11-21 05:38AM
Dec-08-21 08:35AM
Dec-07-21 12:29PM
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brege LauraDirectorJan 12Option Exercise17.0112,500212,62512,500Jan 17 05:17 PM
BAKER BROS. ADVISORS LPDirectorJan 12Option Exercise5.2230,000156,60038,484,981Jan 17 04:22 PM
Brege LauraDirectorJan 12Sale18.2512,500228,1250Jan 17 05:17 PM
DAVIS STEPHENCEOJan 09Sale17.133,90466,87784,633Jan 10 08:38 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryJan 09Sale17.1358910,09018,697Jan 10 08:20 PM
Teehan BrendanEVP, COO, Head of CommercialJan 09Sale17.135329,1134,549Jan 10 08:30 PM
Stankovic Srdjan R.PresidentNov 21Sale15.071,84727,83461,234Nov 22 04:34 PM
Stankovic Srdjan R.PresidentOct 15Sale15.811,32620,96456,831Oct 18 09:22 PM
DAVIS STEPHENCEOOct 15Sale15.812,80444,33179,009Oct 18 09:16 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 09Sale17.9165311,6953,342Jun 10 08:51 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 08Option Exercise0.001,89303,995Jun 10 08:51 PM
DAVIS STEPHENCEOMay 02Sale18.185,48399,69175,875May 03 08:58 PM
Stankovic Srdjan R.PresidentMay 02Sale18.182,86552,09155,188May 03 08:55 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryMay 02Sale18.1889416,25516,742May 03 08:51 PM
Teehan BrendanEVP, COO, Head of CommercialMay 02Sale18.1855210,0363,437May 03 08:47 PM
Kihara JamesPrincipal Accounting OfficerApr 08Sale27.051,02527,7262,433Apr 11 08:02 PM
Stankovic Srdjan R.PresidentFeb 23Option Exercise0.004,919049,938Feb 25 05:41 PM
Teehan BrendanEVP, COO, Head of CommercialFeb 23Option Exercise0.001,10602,894Feb 25 05:45 PM
Kihara JamesPrincipal Accounting OfficerFeb 23Option Exercise0.008400840Feb 25 05:45 PM
DAVIS STEPHENCEOFeb 23Option Exercise0.0010,945069,661Feb 25 05:40 PM
KIM AUSTIN D.EVP & General CounselFeb 23Option Exercise0.002,213015,413Feb 25 05:42 PM
Teehan BrendanEVP, COO, Head of CommercialFeb 23Sale23.8047211,2342,422Feb 25 05:45 PM
Stankovic Srdjan R.PresidentFeb 23Sale23.801,50135,72448,437Feb 25 05:41 PM
Kihara JamesPrincipal Accounting OfficerFeb 23Sale23.803598,544481Feb 25 05:45 PM
KIM AUSTIN D.EVP & General CounselFeb 23Sale23.8078218,61214,631Feb 25 05:42 PM
DAVIS STEPHENCEOFeb 23Sale23.803,92893,48665,733Feb 25 05:40 PM